NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.40 +0.05 (+2.13 %) (As of 07/22/2018 04:00 PM ET)Previous Close$2.40Today's Range$2.40 - $2.4052-Week Range$2.00 - $5.00Volume174 shsAverage Volume9,725 shsMarket Capitalization$52.51 millionP/E RatioN/ADividend YieldN/ABeta-0.79 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California. Receive NBY News and Ratings via Email Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolNYSEAMERICAN:NBY CUSIPN/A Webnovabay.com Phone+1-510-8998800 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-59.81% Return on Equity-389.40% Return on Assets-84.88% Miscellaneous EmployeesN/A Outstanding Shares17,090,000Market Cap$52.51 NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions What is NovaBay Pharmaceuticals' stock symbol? NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY." When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work? Shares of NovaBay Pharmaceuticals reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.07. The biopharmaceutical company had revenue of $2.95 million for the quarter, compared to analysts' expectations of $4.88 million. NovaBay Pharmaceuticals had a negative return on equity of 389.40% and a negative net margin of 59.81%. View NovaBay Pharmaceuticals' Earnings History. What price target have analysts set for NBY? 4 analysts have issued 1-year price objectives for NovaBay Pharmaceuticals' stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate NovaBay Pharmaceuticals' share price to reach $5.3333 in the next twelve months. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Ratings for NovaBay Pharmaceuticals. What is the consensus analysts' recommendation for NovaBay Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of NovaBay Pharmaceuticals' key competitors? Some companies that are related to NovaBay Pharmaceuticals include Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH) and Oncolytics Biotech (ONC). Who are NovaBay Pharmaceuticals' key executives? NovaBay Pharmaceuticals' management team includes the folowing people: Mr. Mark M. Sieczkarek M.B.A., Chairman, CEO & Pres (Age 63)Mr. John J. McGovern, CFO & Treasurer (Age 61)Mr. Justin M. Hall, Sr. VP, Gen. Counsel & Corp. Sec. (Age 40)Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59)Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 73) Has NovaBay Pharmaceuticals been receiving favorable news coverage? News articles about NBY stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NovaBay Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NovaBay Pharmaceuticals' stock price today? One share of NBY stock can currently be purchased for approximately $2.40. How big of a company is NovaBay Pharmaceuticals? NovaBay Pharmaceuticals has a market capitalization of $52.51 million. How can I contact NovaBay Pharmaceuticals? NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800. MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 104 (Vote Outperform)Underperform Votes: 100 (Vote Underperform)Total Votes: 204MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?